Return

ERAPi: Novel inhibitors of Endoplasmic-Reticulum Aminopeptidases (ERAPs) for for the treatment of psoriasis and other autoimmune diseases.

Description

1st ERAP2 selective inhibitors
Several series of ERAP1 inhibitors

Achievements :

•More than 100 analogues
•IC50s from 200 nM to 4 nM
•ERAP2 potent selective inhibitors: KTGS chemistry
•Good ADME properties (on current ERAP2 lead)
 

•In vivo PoC on a psoriasis model
•ERAP-humanized animal created and available

Sheet

Download the offer

Fields

Medical and health technologies